nasdaq:neo
|
442348
|
Mar 23rd, 2024 12:00AM
|
NeoGenomics Laboratories
|
29K
|
1436
|
Open
|
|
Mar 22nd, 2024 11:59PM
|
Mar 23rd, 2024 07:08PM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 22nd, 2024 12:00AM
|
NeoGenomics Laboratories
|
29K
|
1436
|
Open
|
|
Mar 21st, 2024 11:49PM
|
Mar 22nd, 2024 06:56PM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 21st, 2024 12:00AM
|
NeoGenomics Laboratories
|
29K
|
1436
|
Open
|
|
Mar 21st, 2024 12:02AM
|
Mar 21st, 2024 05:40PM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 20th, 2024 12:00AM
|
NeoGenomics Laboratories
|
29K
|
1431
|
Open
|
|
Mar 20th, 2024 12:43AM
|
Mar 20th, 2024 07:41PM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 19th, 2024 12:00AM
|
NeoGenomics Laboratories
|
29K
|
1431
|
Open
|
|
Mar 18th, 2024 11:38PM
|
Mar 19th, 2024 06:13PM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 18th, 2024 12:00AM
|
NeoGenomics Laboratories
|
29K
|
1431
|
Open
|
|
Mar 17th, 2024 11:59PM
|
Mar 18th, 2024 07:25PM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 16th, 2024 12:00AM
|
NeoGenomics Laboratories
|
28K
|
1430
|
Open
|
|
Mar 15th, 2024 11:29PM
|
Mar 16th, 2024 07:13PM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 15th, 2024 12:00AM
|
NeoGenomics Laboratories
|
28K
|
1430
|
Open
|
|
Mar 15th, 2024 01:12AM
|
Mar 15th, 2024 09:03AM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 14th, 2024 12:00AM
|
NeoGenomics Laboratories
|
28K
|
1430
|
Open
|
|
Mar 13th, 2024 11:27PM
|
Mar 14th, 2024 12:24PM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|
nasdaq:neo
|
442348
|
Mar 13th, 2024 12:00AM
|
NeoGenomics Laboratories
|
28K
|
1430
|
Open
|
|
Mar 12th, 2024 11:22PM
|
Mar 13th, 2024 10:55AM
|
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
|
Open
|
Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
|
Open
|
9490 NeoGenomics Way
|
Fort Myers
|
Florida
|
US
|
33912
|
|
NeoGenomics
|
|
Health Care Equipment & Services
|